Clinical Research Papers:
Cecropin Amelittin mutant is a potential therapeutic agent in treating bacterial gastroenteritis
Metrics: PDF 689 views | Full Text 906 views
Shengyue Ji1,*, Liang Chen1,*, Weili Li1, Xiangfang Tang1, Qingshi Meng1 and Hongfu Zhang1
1Key Laboratory of Animal Nutrition, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China
*These authors contributed equally to this work
Correspondence to:
Hongfu Zhang, email: [email protected]
Keywords: CAM-W; in vitro cytotoxicity; acute oral toxicity test; bioavailability
Received: October 16, 2017 Accepted: December 01, 2017 Published: December 22, 2017
ABSTRACT
Cecropin A-melittin mutant (CAM-W) is a novel antimicrobial peptide with promising proteolytic stability and in vitro activity against bacteria and fungi associated with gastroenteritis. To assess the clinical value of CAM-W for treatment of bacterial gastroenteritis, we tested CAM-W in a HT-29 cell line model and a Kunming murine model challenged with Shiga toxin-producing E. coli (STEC) strains. Our results showed that CAM-W is 100% protective in Kunming mice challenged with STEC strains. Moreover, CAM-W exhibited only moderate cytotoxicity against HT‒29 cells (IC50 > 300 mg/L), and oral administration of a single dose of CAM-W (5000 mg/kg) caused no observable side effects in mice. Notably, little if any CAM-W entered the bloodstream of treated mice. These findings demonstrate the potential utility of CAM-W for treatment of bacterial gastroenteritis and provide a basis for further investigation.